MQX-503 FDA Approval Status
FDA Approved: No
Brand name: MQX-503
Dosage form: Topical Formulation
Company: MediQuest Therapeutics Inc
Treatment for: Raynaud's Disease
MQX-503 is a locally acting, topical formulation that is designed to be applied to prevent or treat the symptoms associated with Raynaud's Disease.
Development Timeline for MQX-503
|Apr 29, 2008||MediQuest Therapeutics Submits New Drug Application to FDA for MQX-503 to treat Raynaud's Disease|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.